Bryan J. Schneider, M.D.
I have been interested in the care of cancer patients since I was a junior at the University of Notre Dame. My training at the Indiana University School of Medicine gave me strong clinical skills, but my Oncology training at the University of Michigan helped me realize the need for better treatment for our patients. Lung cancer research is behind many of the other cancers and better therapy is desperately needed for a disease that afflicts over 160,000 Americans annually. I was offered a faculty position at every major medical center in the city, but chose Weill Cornell because of the sincere commitment to excellent patient care while fostering cutting-edge research to help take better care of future patients.
Dr. Bryan J. Schneider is an Assistant Professor of Medicine in the department of Internal Medicine, Division of Hematology/Oncology at New York Presbyterian-Weill Cornell Medical Center.
Dr. Schneider completed his undergraduate studies at the University of Notre Dame in 1994. He pursued his medical education at Indiana University School of Medicine and graduated from the program in 1998. He completed his Internal Medicine Residency training at Indiana University Medical Center, Indianapolis, in 2001, and served as Chief Resident the following year. After completion of his Hematology and Medical Oncology Fellowship at the University of Michigan in Ann Arbor, he assumed the position of Assistant Professor in Medicine at the University of Michigan Comprehensive Cancer Center until 2008.
Dr. Schneider teaches medical students, residents and Hematology/Oncology fellows on all levels. He is a member of numerous medical societies, including the American Society of Clinical Oncology and the International Association for the Study of Lung Cancer. His research focuses on the development of more effective and less toxic therapy for lung and esophageal cancer.
Dr. Schneider is married and has a cat.
Insurance Plans Accepted
The following represents most of the managed care plans accepted by this physician. If your insurance carrier does not appear here please contact the physician’s office as they may have individual contracts not included on this site.
* indicates this physician is no longer accepting new patients with this insurance plan.
- AETNA [HMO]
- AETNA [PPO]
- AETNA [Medicare]
- Aetna - Weill Cornell [POS]
- Affinity Essential
- Affinity Health Plan
- Blue Priority Network
- Emblem Select Care
- Empire Blue Cross/Blue Shield [Pathway X]
- Empire Blue Cross/Blue Shield [Pathway X Enhanced]
- Empire Blue Cross/Blue Shield [PPO]
- Empire Blue Cross/Blue Shield [EPO]
- Empire Blue Cross/Blue Shield [HMO]
- Empire Blue Cross/Blue Shield [Mediblue (Senior)]
- Fidelis Care
- GHI [CBP]
- Health First
- Health Insurance Plan of NY (HIP) [Medicare]
- Health Insurance Plan of NY (HIP) [Medicaid]
- Health Insurance Plan of NY (HIP)
- Health Plus - Amerigroup [CHP]
- Health Plus - Amerigroup
- Health Republic
- Oxford Health Plans [Liberty]
- Oxford Health Plans [Medicare Advantage]
- Oxford Health Plans [Freedom]
- Rockefeller University - CoreSource
- UHC Compass
- United Empire
- United Health Care
- United Health Care [Medicare]
- United Health Care [Community Plan]
- VNSNY CHOICE Medicare [Medicare]
- VNSNY CHOICE Medicare [HMO]
1. Goodrum, K.J., L.L. McCormick, and B.J. Schneider. Group B streptococcus-induced nitric oxide production in murine macrophages is CR3 (CD11b/CD18) Dependent. Infection and Immunity 1994; 62:3102-3107.
2. Schneider BJ, Avram AM, Shulkin BL, Kalemkerian GP. False-positive findings with positron emission tomography in non-small cell lung cancer. Clinical Advances in Hematology & Oncology 2005; 3(7):571-573.
3. Schneider BJ, Ben-Josef E, McGinn C, Chang A, Colletti L, Normolle D, Lawrence T, Zalupski M. Capecitabine and radiation therapy preceded and followed by combination chemotherapy in advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2005; 63(5):1325-1330.
4. Avram AM, Mackie GC, Schneider BJ, Kalemkerian GP, Shulkin BL. Differentiation between carcinoid and sarcoid with FDG-PET and 111-In-Octreotide. Clinical Nuclear Medicine 2006; 31(4):197-200.
5. Schneider BJ and Urba SG. Pre-operative chemoradiation for the treatment of locoregional esophageal cancer: the standard of care? Semin Radiat Oncol 2007; 17:45-52.
6. Schneider BJ, El-Rayes B, Muler JH, Philip PA, Kalemkerian GP, Griffith KA, Zalupski MM. Phase II trial of carboplatin, gemcitabine and capecitabine in patients with carcinoma of unknown primary site. Cancer 2007; 110:770-775.
7. Schneider, BJ. Management of recurrent small cell lung cancer. JNCCN 2008; 6:323-331.
8. Schneider BJ, Kalemkerian GP. Lung cancer: Treatment of non-small cell lung cancer in the elderly. CancerNews.com: http://www.cancernews.com/data/Article/273.asp, 2005.
Honors and Awards
Chief Medical Residency Indiana University Medical School
UMMHC Shining Star Award: One of five hospital employees and the only physician to be awarded this for outstanding contribution to the overall mission, vision and values of the University of Michigan Hospitals and Health Centers.
- Medical Oncology
- Lung Cancer
- Medical Oncology
- Internal Medicine
- M.D., Indiana University School of Medicine, 1998